Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Randomized Controlled Clinical Trial on Direct Oral Novel Anticoagulants for Improving the Prognosis of Cirrhotic Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis

NCT07602062 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07602062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07602062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Randomized Controlled Clinical Trial on Direct Oral Novel Anticoagulants for Improving the Prognosis of Cirrhotic Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
December 31, 2027
Enrollment
175 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulant therapy, portal vein thrombosis, variceal bleeding